Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer

Elevated PI3K signaling drives multiple Breast Cancer subtypes

(2015) Jessica Adams et al.   Oncotarget

Abstract S6-07: Genomic characterisation of metastatic samples from breast cancer patients using next generation sequencing

(2014) T Bachelot et al.   CANCER RESEARCH

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

(2014) Terence O'Reilly et al.   Translational Oncology

Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence ofde novoor acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor

(2013) Paul Vilquin et al.   INTERNATIONAL JOURNAL OF CANCER

Activation of rapid oestrogen signalling in aggressive human breast cancers

(2012) Coralie Poulard et al.   EMBO Molecular Medicine

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer

(2012) Xiaoxian Li et al.   MODERN PATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study

(2012) Olivier Trédan et al.   Targeted Oncology

The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer

(2011) R. Wendel Naumann   GYNECOLOGIC ONCOLOGY

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

(2010) Todd W. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

(2010) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

(2009) Matthew J. Ellis et al.   BREAST CANCER RESEARCH AND TREATMENT

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

(2009) Regan M. Memmott et al.   CELLULAR SIGNALLING

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

(2008) Arkaitz Carracedo et al.   JOURNAL OF CLINICAL INVESTIGATION